A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.

MLA

Rheault, Michelle N., et al. “A Randomized Controlled Trial of Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Kidney Transplant (PRI-VENT FSGS): Protocol and Study Design.” Frontiers in Nephrology, vol. 3, May 2023, p. 1181076. EBSCOhost, https://doi.org/10.3389/fneph.2023.1181076.

APA

Rheault, M. N., Amaral, S., Bock, M., Chambers, E. T., Chavers, B., Ters, M. E., Garro, R., Gbadegesin, R., Govil, A., Harshman, L., Amer, H., Hooper, D. K., Israni, A. K., Riad, S., Sageshima, J., Shapiro, R., Seifert, M., Smith, J., Sung, R., … Verghese, P. S. (2023). A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design. Frontiers in Nephrology, 3, 1181076. https://doi.org/10.3389/fneph.2023.1181076

Chicago

Rheault, Michelle N, Sandra Amaral, Margret Bock, Eileen Tsai Chambers, Blanche Chavers, Mireile El Ters, Rouba Garro, et al. 2023. “A Randomized Controlled Trial of Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Kidney Transplant (PRI-VENT FSGS): Protocol and Study Design.” Frontiers in Nephrology 3 (May): 1181076. doi:10.3389/fneph.2023.1181076.